Sorafenib-induced acute-on-chronic liver failure in a patient with hepatocellular carcinoma after transarterial chemoembolization and radiofrequency ablation: A case report

Wang,Qing‑Liang; Li,Xiao‑Jie; Yao,Zhi‑Cheng; Zhang,Peng; Xu,Shi‑Lei; Huang,He; Hu,Kun‑Peng

doi:10.3892/mco.2017.1363

October-2017 Volume 7 Issue 4

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

October-2017 Volume 7 Issue 4

Full Size Image

Case Report

Sorafenib-induced acute-on-chronic liver failure in a patient with hepatocellular carcinoma after transarterial chemoembolization and radiofrequency ablation: A case report

Authors:
- Qing‑Liang Wang
- Xiao‑Jie Li
- Zhi‑Cheng Yao
- Peng Zhang
- Shi‑Lei Xu
- He Huang
- Kun‑Peng Hu
View Affiliations / Copyright

Affiliations: Department of General Surgery, Lingnan Hospital, The Third Affiliated Hospital of Sun Yat‑sen University, Guangzhou, Guangdong 510530, P.R. China, Department of Laboratory Medicine, Lingnan Hospital, The Third Affiliated Hospital of Sun Yat‑sen University, Guangzhou, Guangdong 510530, P.R. China
Pages: 693-695
|
Published online on: August 3, 2017

https://doi.org/10.3892/mco.2017.1363
Expand metrics +

Abstract

Comprehensive treatments together with sorafenib provide a survival beneﬁt for patients with advanced hepatocellular carcinoma (HCC). Acute‑on‑chronic liver failure (ACLF) is an increasingly recognized distinct entity; however, only few cases induced by sorafenib have been reported to date. We herein present a rare case of ACLF in a patient under treatment with sorafenib. A 63‑year‑old woman who suffered from hepatitis B for 10 years was admitted to our hospital. A computed tomography (CT) scan led to a diagnosis of HCC in the V/VIII hepatic segment, with invasion of the middle hepatic and the right portal veins. The patient received multidisciplinary treatment, including transarterial chemoembolization, radiofrequency ablation and sorafenib. Two months after sorafenib treatment, the patient was readmitted due to progressive jaundice and ACLF was diagnosed by liver biopsy shortly thereafter. Although aggressive treatment was administered, the patient succumbed to the disease following rapid deterioration of her clinical condition. The majority of patients with HCC have underlying liver disease and combination therapy with sorafenib should be administered with caution, as it may increase the risk of severe hepatotoxicity. The present case suggests that patients treated with sorafenib may require a dose reduction following interventional treatment.

View Figures

View References

1	Gomaa AI and Waked I: Recent advances in multidisciplinary management of hepatocellular carcinoma. World J Hepatol. 7:673–687. 2015. View Article : Google Scholar : PubMed/NCBI
2	Jalan R, Gines P, Olson JC, Mookerjee RP, Moreau R, Garcia-Tsao G, Arroyo V and Kamath PS: Acute-on chronic liver failure. J Hepatol. 57:1336–1348. 2012. View Article : Google Scholar : PubMed/NCBI
3	Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
4	Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar : PubMed/NCBI
5	Bruix J and Sherman M: American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma: An update. Hepatology. 53:1020–1022. 2011. View Article : Google Scholar : PubMed/NCBI
6	Arizumi T, Ueshima K, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, et al: Validation of the criteria of transcatheter arterial chemoembolization failure or refractoriness in patients with advanced hepatocellular carcinoma proposed by the LCSGJ. Oncology. (87 Suppl 1). 32–36. 2014. View Article : Google Scholar : PubMed/NCBI
7	Ozenne V, Paradis V, Pernot S, Castelnau C, Vullierme MP, Bouattour M, Valla D, Farges O and Degos F: Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib. Eur J Gastroenterol Hepatol. 22:1106–1110. 2010. View Article : Google Scholar : PubMed/NCBI
8	Ogasawara S, Kanai F, Obi S, Sato S, Yamaguchi T, Azemoto R, Mizumoto H, Koushima Y, Morimoto N, Hirata N, et al: Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma. Hepatol Int. 5:850–856. 2011. View Article : Google Scholar : PubMed/NCBI
9	Jalan R and Williams R: Acute-on-chronic liver failure: Pathophysiological basis of therapeutic options. Blood Purif. 20:252–261. 2002. View Article : Google Scholar : PubMed/NCBI
10	Liu Q, Liu Z, Wang T, Wang Q, Shi X and Dao W: Characteristics of acute and sub-acute liver failure in China: Nomination, classification and interval. J Gastroenterol Hepatol. 22:2101–2106. 2007. View Article : Google Scholar : PubMed/NCBI
11	Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY, Takayama T, Yoon JH, Hori T, Kumada H, Hayashi N, et al: Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer. 47:2117–2127. 2011. View Article : Google Scholar : PubMed/NCBI
12	Fu QH, Zhang Q, Bai XL, Hu QD, Su W, Chen YW, Su RG and Liang TB: Sorafenib enhances effects of transarterial chemoembolization for hepatocellular carcinoma: A systematic review and meta-analysis. J Cancer Res Clin Oncol. 140:1429–1440. 2014. View Article : Google Scholar : PubMed/NCBI
13	Liu L, Chen H, Wang M, Zhao Y, Cai G, Qi X and Han G: Combination therapy of sorafenib and TACE for unresectable HCC: A systematic review and meta-analysis. PLoS One. 9:e911242014. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Sorafenib-induced acute-on-chronic liver failure in a patient with hepatocellular carcinoma after transarterial chemoembolization and radiofrequency ablation: A case report

This article is mentioned in:

Abstract

Figure 1

Figure 2

Related Articles